We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
- Authors
Stewart, J Simon W; Cohen, Ezra E W; Licitra, Lisa; Van Herpen, Carla M L; Khorprasert, Chonlakiet; Soulieres, Denis; Vodvarka, Pavel; Rischin, Danny; Garin, Avgust M; Hirsch, Fred R; Varella-Garcia, Marileila; Ghiorghiu, Serban; Hargreaves, Laura; Armour, Alison; Speake, Georgina; Swaisland, Alan; Vokes, Everett E
- Abstract
To compare survival in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated with gefitinib 250 or 500 mg/day or standard methotrexate.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 11, p1864
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.17.0530